AACR2020-BT-001
Jean-Baptiste Marchand et al.
AACR 2020
Download the poster here
Poster Presentation
BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment
Par alcyon|2020-06-23T11:26:39+02:00juin 22nd, 2020|BT-001, Invir.IO, Publication|Commentaires fermés sur BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment
À propos de l'auteur : alcyon
Articles similaires
- Transgene et BioInvent obtiennent l’autorisation IND « Investigational New Drug » de la FDA américaine pour BT-001, un virus oncolytique contre les tumeurs solides
Transgene et BioInvent obtiennent l’autorisation IND « Investigational New Drug » de la FDA américaine pour BT-001, un virus oncolytique contre les tumeurs solides
- Oncolytic virus TG6002 locates to tumors after intravenous infusion and induces tumor-specific expression of a functional pro-drug activating enzyme in patients with advanced gastrointestinal carcinomas
Oncolytic virus TG6002 locates to tumors after intravenous infusion and induces tumor-specific expression of a functional pro-drug activating enzyme in patients with advanced gastrointestinal carcinomas
